DK0980263T3 - Kombinationsprodukt, som kombinerer en nukleinsyre med en substans, der opløser den ekstracellulære matrix, til genterapi - Google Patents

Kombinationsprodukt, som kombinerer en nukleinsyre med en substans, der opløser den ekstracellulære matrix, til genterapi

Info

Publication number
DK0980263T3
DK0980263T3 DK98928391T DK98928391T DK0980263T3 DK 0980263 T3 DK0980263 T3 DK 0980263T3 DK 98928391 T DK98928391 T DK 98928391T DK 98928391 T DK98928391 T DK 98928391T DK 0980263 T3 DK0980263 T3 DK 0980263T3
Authority
DK
Denmark
Prior art keywords
nucleic acid
extracellular matrix
gene therapy
dissolves
substance
Prior art date
Application number
DK98928391T
Other languages
English (en)
Inventor
Serge Braun
Original Assignee
Transgene Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Transgene Sa filed Critical Transgene Sa
Application granted granted Critical
Publication of DK0980263T3 publication Critical patent/DK0980263T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Public Health (AREA)
  • Plant Pathology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
DK98928391T 1997-05-29 1998-05-29 Kombinationsprodukt, som kombinerer en nukleinsyre med en substans, der opløser den ekstracellulære matrix, til genterapi DK0980263T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9706600A FR2763958A1 (fr) 1997-05-29 1997-05-29 Produit de combinaison associant un acide nucleique a une substance desorganisant la matrice extracellulaire pour la therapie genique
PCT/FR1998/001084 WO1998053853A1 (fr) 1997-05-29 1998-05-29 Produit de combinaison associant un acide nucleique a une substance desorganisant la matrice extracellulaire pour la therapie genique

Publications (1)

Publication Number Publication Date
DK0980263T3 true DK0980263T3 (da) 2003-02-03

Family

ID=9507375

Family Applications (1)

Application Number Title Priority Date Filing Date
DK98928391T DK0980263T3 (da) 1997-05-29 1998-05-29 Kombinationsprodukt, som kombinerer en nukleinsyre med en substans, der opløser den ekstracellulære matrix, til genterapi

Country Status (12)

Country Link
US (1) US6258791B1 (da)
EP (1) EP0980263B1 (da)
JP (1) JP2002500662A (da)
AT (1) ATE224736T1 (da)
AU (1) AU752146B2 (da)
CA (1) CA2291590A1 (da)
DE (1) DE69808274T2 (da)
DK (1) DK0980263T3 (da)
ES (1) ES2181234T3 (da)
FR (1) FR2763958A1 (da)
PT (1) PT980263E (da)
WO (1) WO1998053853A1 (da)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0998945A1 (en) * 1998-09-30 2000-05-10 Transgene S.A. Use of magnesium (Mg2+) for the enhancement of gene delivery in gene therapy
US7691370B2 (en) 1998-10-15 2010-04-06 Canji, Inc. Selectivity replicating viral vector
AU2038900A (en) * 1998-12-04 2000-06-26 Genzyme Corporation Methods for increasing the efficiency of gene transfer
DE59906392D1 (de) * 1998-12-23 2003-08-28 Esparma Gmbh Hyaluronatlyase als penetrationsförderer in topischen mitteln
IL152420A0 (en) * 2001-02-23 2003-05-29 Novartis Ag Novel oncolytic adenoviral vectors
US20050004055A1 (en) * 2001-11-26 2005-01-06 Elena Fattori Increasing electro-gene transfer of nucleic acid molecules into host tissue
EP1480656A4 (en) * 2002-02-15 2007-07-18 Res Dev Foundation ADENOVIRAL TRANDUCTION INDUCED BY HYALURONIC ACID
DE10211457A1 (de) * 2002-03-12 2003-09-25 Knoell Hans Forschung Ev Verwendung von Hyaluronatlyase zur Behandlung von Myokardinfarkten
AU2003220115A1 (en) * 2002-05-20 2003-12-12 Board Of Regents, The University Of Texas System Methods and compositions for delivering enzymes and nucleic acid molecules to brain, bone, and other tissues
WO2004098534A2 (en) * 2003-02-24 2004-11-18 Therion Biologics Corporation Methods for delivering angiogenic modulators using pox viruses
EP2330213A1 (en) 2003-03-05 2011-06-08 Halozyme, Inc. Soluble hyaluronidase glycoprotein (sHASEGP), process for preparing the same, uses and pharmaceutical compositions comprising thereof
US20050014714A1 (en) * 2003-06-04 2005-01-20 The Johns Hopkins University Gene delivery to organs
ES2356154T3 (es) 2003-07-21 2011-04-05 Transgene S.A. Citoquinas multifuncionales.
US7888201B2 (en) * 2003-11-04 2011-02-15 Taiwan Semiconductor Manufacturing Company, Ltd. Semiconductor-on-insulator SRAM configured using partially-depleted and fully-depleted transistors
US7572613B2 (en) * 2004-06-25 2009-08-11 Klein Jeffrey A Drug delivery system for accelerated subcutaneous absorption
JP2007175021A (ja) * 2005-12-28 2007-07-12 Sysmex Corp 大腸がんのリンパ節転移マーカー
ES2441961T3 (es) * 2007-02-15 2014-02-07 Allergan, Inc. Composiciones de toxina botulínica y métodos
US8357531B2 (en) 2007-07-03 2013-01-22 Transgene S.A. Immortalized avian cell lines
WO2010138918A1 (en) * 2009-05-29 2010-12-02 Pacira Pharmaceuticals, Inc. Hyaluronidase as an adjuvant for increasing the injection volume and dispersion of large diameter synthetic membrane vesicles containing a therapeutic agent
JP6194248B2 (ja) 2010-10-28 2017-09-06 パシラ ファーマシューティカルズ インコーポレーテッド 非ステロイド性抗炎症薬の徐放性処方物
JP6430949B2 (ja) 2012-10-23 2018-11-28 エモリー ユニバーシティ Ｇｍ−ｃｓｆとｉｌ−４のコンジュゲート、組成物、ならびにそれに関連する方法
CN110418650A (zh) 2016-11-16 2019-11-05 免疫治疗有限公司 用于治疗过敏的核酸
CN109983013A (zh) 2016-11-18 2019-07-05 帕西拉制药有限公司 美洛昔康锌复合物微粒多囊脂质体制剂及其制备方法
EP3612556B8 (en) 2017-04-22 2024-11-20 Immunomic Therapeutics, Inc. Improved lamp constructs
WO2018204534A1 (en) 2017-05-02 2018-11-08 Immunomic Therapeutics, Inc. Lamp (lysosomal associated membrane protein) constructs comprising cancer antigens
JP2021523185A (ja) 2018-05-15 2021-09-02 イミュノミック セラピューティックス， インコーポレイテッドＩｍｍｕｎｏｍｉｃ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． アレルゲンを含む改善されたｌａｍｐ構築物
EP3833398A4 (en) 2018-09-21 2021-12-22 University of Connecticut COMPOSITIONS AND METHODS OF RESTORING PATERNAL UBE3A GENE EXPRESSION IN ANGELMAN'S SYNDROME IN HUMANS
KR20220083773A (ko) 2019-10-18 2022-06-20 이뮤노믹 쎄라퓨틱스, 인크. 암 항원을 포함하는 개선된 lamp 구축물
US12564646B2 (en) * 2021-06-16 2026-03-03 BioViva USA, Inc. Treatment of age-related cognitive decline using genetically modified viral vectors
CA3247515A1 (en) 2022-04-10 2023-10-19 Immunomic Therapeutics, Inc. Bicistronic lamp constructions comprising genes that enhance the immune response and methods of their use

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991012329A2 (en) * 1990-02-12 1991-08-22 Board Of Regents, The University Of Texas System Satellite cell proliferation in adult skeletal muscle
HRP930935A2 (en) * 1992-06-11 1994-12-31 Astra Ab New dna sequences
US5739118A (en) * 1994-04-01 1998-04-14 Apollon, Inc. Compositions and methods for delivery of genetic material
FR2732895B1 (fr) 1995-04-11 1997-05-16 Pasteur Merieux Serums Vacc Utilisation d'un compose amphipathique cationique comme agent de transfection, comme adjuvant de vaccin, ou comme medicament
US5858351A (en) 1996-01-18 1999-01-12 Avigen, Inc. Methods for delivering DNA to muscle cells using recombinant adeno-associated virus vectors
US6177410B1 (en) 1997-12-05 2001-01-23 Vanderbilt University Therapeutic methods for prostate cancer

Also Published As

Publication number Publication date
ATE224736T1 (de) 2002-10-15
FR2763958A1 (fr) 1998-12-04
US6258791B1 (en) 2001-07-10
DE69808274D1 (de) 2002-10-31
JP2002500662A (ja) 2002-01-08
AU8023898A (en) 1998-12-30
AU752146B2 (en) 2002-09-05
CA2291590A1 (fr) 1998-12-03
PT980263E (pt) 2003-02-28
EP0980263A1 (fr) 2000-02-23
WO1998053853A1 (fr) 1998-12-03
EP0980263B1 (fr) 2002-09-25
ES2181234T3 (es) 2003-02-16
DE69808274T2 (de) 2003-05-15

Similar Documents

Publication Publication Date Title
DE69808274D1 (de) Kombinationsprodukt, enthaltend eine nukleinsäure und eine substanz, die die extrazellulärematrix desorganisiert, zur verwendung in gentherapie
ATE228507T1 (de) Substituierte 6-phenylphenanthridine
DE69942459D1 (de) Isolierte nukleinsäuremoleküle die t-zellen induzierbare faktoren kodieren (tif), kodierte proteine und ihre anwendung
BR0007527A (pt) Fenilfenantridinas com atividade inibitória depde-iv
TR200103186T2 (tr) MEK enzimlerinin inhibitörleri olarak kinolin türevleri
TR200000927T2 (tr) Prostaglandin agonistleri ve kemik bozukluklarının tedavisi
DE69940769D1 (de) Orale flüssige zusammensetzungen
TR199900920T2 (xx) Nafthiridin t�revleri.
BR0010220A (pt) Compostos de pirimidinona
FI93831B (fi) Tetratsolit, jotka ovat verenpainetta alentavien yhdisteiden välituotteita
BRPI0515012A (pt) substáncia quìmica, composição e formulação farmacêutica, método de tratamento, método de inibição de pelo menos uma enzima que utiliza atp e uso
NO20043257D0 (no) Innkapslede bindingsproteiner som biosensorer
NO20034230D0 (no) 1,2,3,4-tetrahydroisokinolin-derivater som urotensin II reseptor-antagonister
ATE396993T1 (de) Tetrahydropyranyl-cyclopentyl- tetrahydropyridopyridin-modulatoren der chemokin- rezeptor-aktivität
NO971889L (no) Forbindelser og sammensetninger for levering av aktive midler
BR9713465A (pt) Inibidores metalotprotease de amina cìclica sibstituìda
TR200001203T2 (tr) Yeni birleşik maddeler
BR9713338A (pt) Benzonaftiridinas como terapêuticos brÈnquicos.
YU40701A (sh) Piperidini kao modulatori ccr5
ATE231872T1 (de) Thiazolopyrimidinderivate
DE60013098D1 (de) Zusammensetzung zur hautdesinfizierung
DE502004002571D1 (de) Substituierte 3-pyrrolidin-indol-derivate
ATE423562T1 (de) Alpha-ketoamidhaltige multikatalytische protease inhibitoren
DE50204688D1 (de) N-alkylaziridinoprepolymere als dentalmasse
DK0782567T3 (da) Isothiourinstofderivater og fremgangsmåder til deres fremstilling